Results 211 to 220 of about 7,042 (272)

Long‐Term Safety and Efficacy of Once‐Daily and Proactive Twice‐Weekly Roflumilast Cream 0.05% for Mild‐to‐Moderate Atopic Dermatitis in Children Aged 2–5 Years From a 52‐Week, Phase 3 Trial (INTEGUMENT‐OLE)

open access: yesPediatric Dermatology, EarlyView.
ABSTRACT Background INTEGUMENT‐PED/NCT04845620, a 4‐week, phase 3 trial, demonstrated efficacy and safety of roflumilast cream 0.05% in children aged 2–5 years with mild‐to‐moderate atopic dermatitis (AD). A phase 3 open‐label extension trial (INTEGUMENT‐OLE [NCT04804605]) investigated long‐term outcomes continuing roflumilast cream for ≤ 56 weeks ...
Lawrence F. Eichenfield   +14 more
wiley   +1 more source

Engineered surface strategies to manage dental implant‐related infections

open access: yesPeriodontology 2000, EarlyView.
Abstract When exposed to the oral environment, dental implants, like natural surfaces, become substrates for microbial adhesion and accumulation, often leading to implant‐related infections—one of the main causes of implant failure. These failures impose significant costs on patients, clinicians, and healthcare systems.
João Gabriel S. Souza   +7 more
wiley   +1 more source

Sex‐specific metabolic responses to glucagon receptor agonism and modulation of the FGF21‐glucagon axis in female mice

open access: yesThe Journal of Physiology, EarlyView.
Abstract figure legend Therapies targeting the glucagon receptor are being explored for obesity treatment, yet most preclinical studies remain male biased. In this study, Merrild and Johansen et al. show that in diet‐induced obese wild‐type mice a long‐acting glucagon analogue (LA‐Gcg) elicits sexually dimorphic effects on weight loss, food intake ...
Christoffer Merrild   +3 more
wiley   +1 more source

Innovative Inclusion Complexes Clotrimazole: Hydroxypropyl-β-Cyclodextrin-Modified Polyurethane Networks as Carriers for Slow Drug Delivery. [PDF]

open access: yesBiomedicines
Cakić SM   +6 more
europepmc   +1 more source

Rethinking Chlorine: Essential Chemical or Replaceable Risk? [PDF]

open access: yesChemSusChem
Schwan J   +6 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy